LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (the "Company†) (Nasdaq: SVRA), a clinical- stage biopharmaceutical company focused on rare respiratory diseases, today announced additional analyses from its pivotal Phase 3 IMPALA-2 clinical trial of molgramostim in aPAP were presented as poster presentations at the ERS Congress 2025 in Amsterdam, The Netherlands. ERS 2025 Posters Savara Title: Efficacy of Inhaled Molgramostim According to Severity of Autoimmune Pulmonary Alveolar Proteinosis (aPAP). ...

Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to substantial losses incurred as a result of misleading statements made by the company regarding its regulatory submissions and business prospects [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from March 7, 2024, to May 23, 2025, Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient data on its chemistry, manufacturing, and controls [3]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay the submission process beyond what was communicated to investors [3]. - The delay in regulatory approval raised the likelihood that Savara would need to seek additional capital, contradicting the positive statements made by the company regarding its business and operational prospects [3]. Investor Participation - Investors who suffered losses are encouraged to contact the Law Offices of Howard G. Smith before November 7, 2025, to participate in the ongoing class action lawsuit [2][4]. - Participation does not require immediate action; investors may choose to retain counsel or remain absent from the class action [5].

Accessibility StatementSkip Navigation NEW YORK, Sept. 26, 2025 /PRNewswire/ -- Levi &Â Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/ ...

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for alleged violations of securities laws, specifically related to misleading statements regarding its Biologics License Application (BLA) for MOLBREEVI [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from March 7, 2024, to May 23, 2025, with a deadline for lead plaintiff appointments set for November 10, 2025 [2]. - The complaint alleges that Savara made false and misleading statements to the market, particularly regarding the adequacy of information provided in its BLA submitted to the FDA [2]. - It is claimed that the FDA was unlikely to approve Savara's BLA due to deficiencies in the information provided, which rendered the company's public statements materially misleading throughout the class period [2]. Group 2: Shareholder Participation - Shareholders who purchased shares during the specified class period are encouraged to contact the law firm for potential lead plaintiff appointments, although this is not a requirement for recovery [2][3]. - Once registered, shareholders will be enrolled in a portfolio monitoring system to receive updates on the case's status, with no cost or obligation to participate [3]. Group 3: Law Firm Background - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

LOS ANGELES, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 7, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA) securities between March 7, 2024 and May 23, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR SAVARA INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOU ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Savara Inc. regarding a class action lawsuit due to alleged misleading statements related to the approval of the MOLBREEVI BLA treatment for pulmonary alveolar proteinosis [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from March 4, 2024, to May 23, 2025 [1]. - Allegations include that Savara Inc. made materially false and misleading statements about the MOLBREEVI BLA, specifically regarding its chemistry, manufacturing, and controls [1]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which could delay the submission timeline previously communicated to investors [1]. Group 2: Impact on Shareholders - The delay in regulatory approval may increase the likelihood that Savara would need to raise additional capital [1]. - Shareholders are encouraged to register for the class action to monitor the case's progress and potentially seek lead plaintiff status by the deadline of November 7, 2025 [2]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to the alleged false and misleading statements that inflated the company's stock price [3].

Core Viewpoint - A class action lawsuit has been filed against Savara Inc. for allegedly misleading investors regarding the viability of its lead drug candidate, MOLBREEVI, during the specified class period [1][2]. Allegations - The lawsuit claims that Savara failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on chemistry, manufacturing, and controls, which made FDA approval unlikely in its current form [2]. - The complaint also states that the company was unlikely to meet its previously communicated timeline for submitting the MOLBREEVI BLA, and the delay increased the likelihood of needing additional capital [2]. Stock Price Impact - Following the announcement of a refusal to file (RTF) letter from the FDA regarding the MOLBREEVI BLA, Savara's stock price dropped by $0.90, or 31.69%, closing at $1.94 per share on May 27, 2025 [3]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by November 7, 2025, although they can remain absent class members if they choose not to take action [4]. Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Savara To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Savara between March 7, 2024 and May 23, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Savara Inc. securities between March 7, 2024, and May 23, 2025, of the upcoming lead plaintiff deadline on November 7, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Savara securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5] - To serve as lead plaintiff, individuals must file a motion with the court by November 7, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Case Allegations - The lawsuit alleges that Savara's defendants made false or misleading statements regarding the MOLBREEVI Biologics License Application, which lacked sufficient information for FDA approval [4] - It is claimed that the delay in regulatory approval increased the likelihood of Savara needing to raise additional capital, contradicting prior representations made to investors [4] - The lawsuit asserts that when the true details became public, investors suffered damages due to the misleading statements [4]

Core Viewpoint - Savara Inc. is facing a class action lawsuit due to alleged securities fraud related to the FDA's refusal to file a Biologics License Application (BLA) for its product MOLBREEVI, which has led to a significant decline in share price [1][2][3]. Group 1: Lawsuit Details - The class action lawsuit is based on claims that Savara made false or misleading statements regarding the completeness of the MOLBREEVI BLA submission [3]. - The FDA's refusal to file letter indicated that the BLA was not sufficiently complete, particularly concerning Chemistry, Manufacturing, and Controls (CMC) [2][3]. - Following the announcement of the FDA's decision, Savara's share price dropped by $0.90, approximately 31.69%, from $2.84 to $1.94 [2]. Group 2: Investor Information - Investors who acquired Savara securities between March 7, 2024, and May 23, 2025, are urged to seek lead plaintiff appointment by the November 7, 2025 deadline [1]. - The law firm Kirby McInerney LLP is handling the case and encourages affected investors to contact them for more information [4][5].